Bioscience of Microbiota, Food and Health
Online ISSN : 2186-3342
ISSN-L : 2186-3342
α-Cyclodextrin supplementation improves endurance exercise performance and reduces post-exercise fatigue in human males: a randomized, double-blind, placebo-controlled, parallel-group study
Makiko ONISHITeppei NAKAMURAChie KANOTatsuhiko HIROTAShinji FUKUDAHiroto MORITA
Author information
JOURNAL OPEN ACCESS Advance online publication

Article ID: 2024-062

Details
Abstract

α-Cyclodextrin (αCD), a cyclic hexasaccharide composed of six glucose units, is not digested in the small intestine but is completely fermented by gut microbes. Recently, we have reported that αCD supplementation for nonathlete men improved their 10 km biking times. However, the beneficial effects of αCD on exercise are not yet fully understood. Therefore, we conducted a randomized, double-blind, placebo-controlled, parallel-group study to confirm the reproducibility and obtain additional data, employing a larger sample size and a greater αCD dose than that used in our previous study. Age, body mass index, estimated VO2 max, and Bacteroides uniformis cell number in feces were used as stratifying factors. Eighty-one healthy nonathlete men aged 20 to 49 years who had exercise habits received a placebo (n=42) or αCD (1 g/day; n=39) for 9 weeks. Similar to our previous study, αCD supplementation significantly improved endurance exercise performance (10 km biking time trial) compared with the placebo (placebo=1,126.4 ± 133.6 s, αCD=1,073.2 ± 116.7 s, p=0.016). In addition, we observed a significantly reduced visual analog scale score for post-exercise fatigue (placebo=59.0 [46.3–54.3] mm, αCD=48.8 [37.0–50.3] mm, p=0.043). The heart rate increase was lower in the αCD group than in the placebo group during exercise (placebo=152.3 ± 11.1 bpm, αCD=144.2 ± 16.3 bpm, p=0.016). These results indicate that αCD supplementation improves endurance exercise performance and reduces post-exercise fatigue in nonathlete men.

Content from these authors
© 2024 by BMFH Press

This article is licensed under a Creative Commons [Attribution-NonCommercial-NoDerivatives 4.0 International] license.
https://creativecommons.org/licenses/by-nc-nd/4.0/
Previous article Next article
feedback
Top